The acquisition brings Lilly a novel in vivo cell therapy platform built around engineered circular RNA and proprietary lipid nanoparticles
This collaboration positions WACKER and RNAV8 as premium mRNA service providers
Collaboration supports multiple discovery efforts, including vaccines
mRNA-based therapies involve the administration of mRNA in patients so that patients' own cells can produce the encoded therapeutic antibody
This next-generation CAR T construct was designed to improve the tolerability profile of conventional CD19 CAR Ts and developed in the laboratory of James N. Kochenderfer, M.D., at the National Cancer Institute, part of the NIH, the same laboratory that discovered axicabtagene ciloleucel
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
This linear, covalently closed, double-stranded DNA offers a rapid, cell-free alternative to traditional plasmid DNA, addressing a critical bottleneck in nucleic acid therapeutics development
The agreement brings to market a method pioneered at CU Boulder that enables the reliable synthesis of long RNA strands
The deal was executed via a merger of Novartis’ wholly owned subsidiary, Ajax Acquisition Sub, Inc., into Avidity
Subscribe To Our Newsletter & Stay Updated
